IN2014DN01950A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN01950A IN2014DN01950A IN1950DEN2014A IN2014DN01950A IN 2014DN01950 A IN2014DN01950 A IN 2014DN01950A IN 1950DEN2014 A IN1950DEN2014 A IN 1950DEN2014A IN 2014DN01950 A IN2014DN01950 A IN 2014DN01950A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004043009A DE102004043009A1 (de) | 2004-09-06 | 2004-09-06 | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| PCT/EP2005/009554 WO2006027207A1 (de) | 2004-09-06 | 2005-09-06 | Transportprotein zum einbringen chemischer verbindungen in nervenzellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01950A true IN2014DN01950A (zh) | 2015-07-10 |
Family
ID=35583367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1950DEN2014 IN2014DN01950A (zh) | 2004-09-06 | 2014-03-14 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8293230B2 (zh) |
| EP (1) | EP1786832B1 (zh) |
| JP (2) | JP5357425B2 (zh) |
| KR (3) | KR101602128B1 (zh) |
| CN (1) | CN101056888B (zh) |
| AU (1) | AU2005281830B2 (zh) |
| BR (1) | BRPI0514943A (zh) |
| CA (1) | CA2578097C (zh) |
| DE (1) | DE102004043009A1 (zh) |
| DK (1) | DK1786832T3 (zh) |
| EA (1) | EA014526B1 (zh) |
| ES (1) | ES2390279T3 (zh) |
| HK (1) | HK1100291A1 (zh) |
| IL (1) | IL181481A (zh) |
| IN (1) | IN2014DN01950A (zh) |
| MX (1) | MX2007002737A (zh) |
| NO (1) | NO340732B1 (zh) |
| UA (1) | UA93359C2 (zh) |
| WO (1) | WO2006027207A1 (zh) |
| ZA (1) | ZA200701896B (zh) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2277854T5 (es) | 1999-08-25 | 2011-02-04 | Allergan, Inc. | Neurotoxinas recombinantes activables. |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| EP1982996A1 (en) | 2004-09-01 | 2008-10-22 | Allergan, Inc. | Degradable clostridial toxins |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| EP1861419B1 (en) * | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| EA012052B1 (ru) | 2005-06-17 | 2009-08-28 | Мерц Фарма Гмбх Унд Ко. Кгаа | Устройство и способ для ферментативного получения биологически активных соединений |
| US20090269358A1 (en) * | 2005-10-07 | 2009-10-29 | Shone Clifford C | Proteins with Improved Solubility and Methods for Producing and Using Same |
| JP2009543556A (ja) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| AU2007272517B2 (en) * | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| WO2008008803A2 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2008169166A (ja) * | 2007-01-14 | 2008-07-24 | Tokyo Univ Of Agriculture & Technology | 糖結合性ポリペプチド、複合材料、及び薬剤送達システム |
| CN101720331A (zh) | 2007-06-01 | 2010-06-02 | 德国麦氏大药厂 | 基于肉毒毒素的神经毒成分供应温度-稳定性肌肉松弛剂的方法 |
| CN101687046B (zh) * | 2007-07-10 | 2012-12-26 | 株式会社美地拓斯 | 稳定性改善的肉毒毒素药物液体组合物 |
| WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| WO2009038770A2 (en) * | 2007-09-20 | 2009-03-26 | University Of Massachusetts Cvip | Detoxified recombinant botulinum neurotoxin |
| US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| EP2072039A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| WO2010014746A1 (en) * | 2008-07-29 | 2010-02-04 | Florida State University Research Foundation | Materials and methods for treatment of spinal muscular atrophy and taxane-induced peripheral neuropathy (tipn) |
| BRPI0916964A2 (pt) | 2008-08-29 | 2015-11-24 | Merz Pharma Gmbh & Co Kgaa | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo |
| EP2161033B1 (en) | 2008-09-09 | 2013-05-01 | Susanne Dr. Grafe | Botulinum toxin to introduce temporal infertiliy in a vertebrate (e.g. human) |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| EP2246065A1 (en) | 2009-04-29 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Intrastriatal botulinum toxin therapy |
| EP2399601A1 (en) | 2010-06-24 | 2011-12-28 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin therapy |
| JP5990176B2 (ja) | 2010-10-12 | 2016-09-07 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤 |
| DK3372239T3 (da) | 2012-05-30 | 2021-02-01 | Harvard College | Manipuleret botulinumneurotoksin |
| EP2897638A1 (en) | 2012-09-24 | 2015-07-29 | Montana State University-Bozeman | Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| BR112015003591B1 (pt) | 2012-11-21 | 2022-02-01 | Ipsen Bioinnovation Limited | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| ES2642916T3 (es) | 2014-06-06 | 2017-11-20 | Galit KLEINER-FISMAN | Toxina botulínica para su uso en el tratamiento de la paratonia |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10549042B2 (en) | 2014-12-23 | 2020-02-04 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled glass syringe |
| US10647750B2 (en) | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| EP3274364B1 (en) | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| KR20180021703A (ko) * | 2015-05-15 | 2018-03-05 | 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 | 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소 |
| JP2018530315A (ja) | 2015-08-27 | 2018-10-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 疼痛の治療を目的とする組成物及び方法 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| CA3002477C (en) * | 2015-11-20 | 2024-01-02 | Colgate-Palmolive Company | Single phase whitening dentifrice with high purity metaphosphate abrasive |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| TWI737742B (zh) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用 |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| EP3519430A1 (en) * | 2016-09-29 | 2019-08-07 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| WO2019243376A1 (en) | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Intramuscular injection of botulinum toxin for the treatment of vulvodynia |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| CA3111674A1 (en) | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| CN117396217A (zh) | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗 |
| JP2024534384A (ja) | 2021-09-16 | 2024-09-20 | イプセン バイオファーム リミテッド | 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| EP4404955A1 (en) | 2021-09-23 | 2024-07-31 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| KR20240116485A (ko) | 2021-11-22 | 2024-07-29 | 입센 바이오팜 리미티드 | 통증의 치료 |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214787B1 (en) | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| GB9410871D0 (en) | 1994-05-31 | 1994-07-20 | Imperial College | Modification of tetanus toxin for use as a transport protein |
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5939070A (en) | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
| US7235521B1 (en) | 1999-05-17 | 2007-06-26 | United States Of America As Represented By The Secretary Of The Army | Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins |
| ES2277854T5 (es) * | 1999-08-25 | 2011-02-04 | Allergan, Inc. | Neurotoxinas recombinantes activables. |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US6787517B1 (en) | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| US7196189B2 (en) | 2001-10-09 | 2007-03-27 | Microbia, Inc. | love variant regulator molecules |
| US20070118934A1 (en) | 2001-10-26 | 2007-05-24 | Planet Biotechnology, Inc. | Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax |
| KR20030097047A (ko) * | 2002-06-18 | 2003-12-31 | 신찬영 | 초음파기화식냉풍기 |
| GB0216865D0 (en) * | 2002-07-19 | 2002-08-28 | Microbiological Res Authority | Targetted agents for nerve regeneration |
| US20040115727A1 (en) | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
| WO2005030119A2 (en) | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| US20050129677A1 (en) | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| GB2416692A (en) * | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| EP1778279B1 (en) * | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| WO2006042149A2 (en) | 2004-10-06 | 2006-04-20 | Allergan, Inc. | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| EP1824971B1 (en) | 2004-11-22 | 2016-01-13 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| EP1861419B1 (en) | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| JP5134540B2 (ja) * | 2005-09-19 | 2013-01-30 | アラーガン、インコーポレイテッド | クロストリジウム毒素活性化クロストリジウム毒素 |
| DE102005051789B4 (de) | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| JP2009543556A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| US8445650B2 (en) | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
-
2004
- 2004-09-06 DE DE102004043009A patent/DE102004043009A1/de not_active Withdrawn
-
2005
- 2005-09-06 CA CA2578097A patent/CA2578097C/en not_active Expired - Fee Related
- 2005-09-06 BR BRPI0514943-6A patent/BRPI0514943A/pt not_active IP Right Cessation
- 2005-09-06 CN CN2005800381125A patent/CN101056888B/zh not_active Expired - Fee Related
- 2005-09-06 DK DK05786305.2T patent/DK1786832T3/da active
- 2005-09-06 EA EA200700408A patent/EA014526B1/ru not_active IP Right Cessation
- 2005-09-06 WO PCT/EP2005/009554 patent/WO2006027207A1/de active Application Filing
- 2005-09-06 MX MX2007002737A patent/MX2007002737A/es active IP Right Grant
- 2005-09-06 UA UAA200702980A patent/UA93359C2/ru unknown
- 2005-09-06 EP EP05786305A patent/EP1786832B1/de active Active
- 2005-09-06 JP JP2007529343A patent/JP5357425B2/ja not_active Expired - Fee Related
- 2005-09-06 KR KR1020147012193A patent/KR101602128B1/ko not_active IP Right Cessation
- 2005-09-06 US US11/661,849 patent/US8293230B2/en active Active
- 2005-09-06 KR KR1020137009238A patent/KR20130043251A/ko active Application Filing
- 2005-09-06 AU AU2005281830A patent/AU2005281830B2/en not_active Ceased
- 2005-09-06 KR KR1020077005567A patent/KR101277280B1/ko not_active IP Right Cessation
- 2005-09-06 ES ES05786305T patent/ES2390279T3/es active Active
-
2007
- 2007-02-21 IL IL181481A patent/IL181481A/en not_active IP Right Cessation
- 2007-03-05 ZA ZA200701896A patent/ZA200701896B/xx unknown
- 2007-04-10 NO NO20071825A patent/NO340732B1/no not_active IP Right Cessation
- 2007-06-18 HK HK07106554.8A patent/HK1100291A1/xx not_active IP Right Cessation
-
2012
- 2012-09-10 US US13/608,631 patent/US9234011B2/en active Active
-
2013
- 2013-02-13 JP JP2013025913A patent/JP5833039B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-14 IN IN1950DEN2014 patent/IN2014DN01950A/en unknown
- 2014-08-05 US US14/451,668 patent/US9422344B2/en active Active